

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to ove...
Q4 2026
Aug 13, 2026
Q3 2026
May 15, 2026
Q2 2026
Mar 31, 2026
Q1 2026
Nov 14, 2025
FY 2025
Aug 14, 2025